Switch to:

Akero Therapeutics Debt-to-Equity

: 0.01 (As of Sep. 2020)
View and export this data going back to 2019. Start your Free Trial

Akero Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $0.30 Mil. Akero Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $1.56 Mil. Akero Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $286.46 Mil. Akero Therapeutics's debt to equity for the quarter that ended in Sep. 2020 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

NAS:AKRO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.01
Current: 0.01

0
0.01

During the past 3 years, the highest Debt-to-Equity Ratio of Akero Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.

NAS:AKRO's Debt-to-Equity is ranked higher than
86% of the 1044 Companies
in the Biotechnology industry.

( Industry Median: 0.09 vs. NAS:AKRO: 0.01 )

Akero Therapeutics Debt-to-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Akero Therapeutics Annual Data
Dec17 Dec18 Dec19
Debt-to-Equity 0.00 0.00 0.00

Akero Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.01

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Akero Therapeutics Debt-to-Equity Distribution

* The bar in red indicates where Akero Therapeutics's Debt-to-Equity falls into.



Akero Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Akero Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Akero Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2020 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Akero Therapeutics  (NAS:AKRO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Akero Therapeutics Debt-to-Equity Related Terms


Akero Therapeutics Debt-to-Equity Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)